TY - JOUR
T1 - Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols
AU - Motlló, Cristina
AU - Ribera, Josep Maria
AU - Morgades, Mireia
AU - Granada, Isabel
AU - Montesinos, Pau
AU - Brunet, Salut
AU - Bergua, Juan
AU - Tormo, Mar
AU - García-Boyero, Raimundo
AU - Sarrà, Josep
AU - del Potro, Eloy
AU - Grande, Carlos
AU - Barba, Pere
AU - Bernal, Teresa
AU - Amigo, María Luz
AU - Grau, Javier
AU - Cervera, José
AU - Feliu, Evarist
PY - 2017/1/2
Y1 - 2017/1/2
N2 - © 2016 Informa UK Limited, trading as Taylor & Francis Group. The karyotype is an important predictor of outcome in acute lymphoblastic leukemia (ALL). Rearrangements of the 11q23 region involving the KMT2A gene confer an unfavorable prognosis. Forty-six adult ALL patients from the PETHEMA Group treated with risk-adapted protocols, with t(v;11q23) were selected for this study. Complete response (CR) was attained in 38 patients; 25 remained in CR after consolidation. Twelve (48%) received allogeneic hematopoietic stem cell transplantation (HSCT) and 13 delayed intensification and maintenance. The 5-year CR duration probability was 37% (95% CI, 19%–55%). A trend for a longer CR duration was observed in patients undergoing HSCT vs. those receiving chemotherapy. The 5-year overall survival (OS) probability was 20% (95% CI, 5%–35%). The OS was better, albeit not significant, in patients with a MRD level <0.1% after induction (39% [95% CI, 14%–64%] vs. 13% [95% CI, 0%–36%]). Specific treatment approaches are required to improve the outcome of patients with KMT2A-rearrangements.
AB - © 2016 Informa UK Limited, trading as Taylor & Francis Group. The karyotype is an important predictor of outcome in acute lymphoblastic leukemia (ALL). Rearrangements of the 11q23 region involving the KMT2A gene confer an unfavorable prognosis. Forty-six adult ALL patients from the PETHEMA Group treated with risk-adapted protocols, with t(v;11q23) were selected for this study. Complete response (CR) was attained in 38 patients; 25 remained in CR after consolidation. Twelve (48%) received allogeneic hematopoietic stem cell transplantation (HSCT) and 13 delayed intensification and maintenance. The 5-year CR duration probability was 37% (95% CI, 19%–55%). A trend for a longer CR duration was observed in patients undergoing HSCT vs. those receiving chemotherapy. The 5-year overall survival (OS) probability was 20% (95% CI, 5%–35%). The OS was better, albeit not significant, in patients with a MRD level <0.1% after induction (39% [95% CI, 14%–64%] vs. 13% [95% CI, 0%–36%]). Specific treatment approaches are required to improve the outcome of patients with KMT2A-rearrangements.
KW - acute lymphoblastic leukemia
KW - KMT2A/MLL
KW - MRD
U2 - 10.1080/10428194.2016.1177182
DO - 10.1080/10428194.2016.1177182
M3 - Article
SN - 1042-8194
VL - 58
SP - 145
EP - 152
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -